Search

Your search keyword '"Pinato, David James"' showing total 78 results
Start Over Author "Pinato, David James"
78 results on '"Pinato, David James"'

51. Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Author

Sarker, Debashis, primary, Sodergren, Mikael, additional, Plummer, Elizabeth Ruth, additional, Basu, Bristi, additional, Meyer, Tim, additional, Huang, Kai-Wen, additional, Evans, T.R. Jeffry, additional, Spalding, Duncan, additional, Ma, Yuk Ting, additional, Palmer, Daniel H., additional, Chee, Cheng Ean, additional, Pinato, David James, additional, Reebye, Vikash, additional, McVeigh, Daniel, additional, Raulf, Nina, additional, Vasara, Jenni, additional, Andrikakou, Pinelopi, additional, Habib, Robert, additional, Blakey, David, additional, and Habib, Nagy A., additional

Published
2020
Full Text
View/download PDF

52. Post-registration experience of nivolumab (nivo) therapy in patients with advanced hepatocellular carcinoma (HCC): An international study.

Author

Fessas, Petros, primary, Kaseb, Ahmed Omar, additional, Wang, Yinghong, additional, Saeed, Anwaar, additional, Szafron, David, additional, Jun, Tomi, additional, Dharmapuri, Sirish, additional, Naqash, Abdul Rafeh, additional, Khan, Uqba, additional, Yu, Bo, additional, Paul, Sonal D, additional, Nimkar, Neil satish, additional, Bettinger, Dominik, additional, Hildebrand, Hannah, additional, Mohamed, Yehia I., additional, Huang, Yi-Hsiang, additional, Rimassa, Lorenza, additional, Ang, Celina, additional, Marron, Thomas Urban, additional, and Pinato, David James, additional

Published
2020
Full Text
View/download PDF

54. PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: A pooled analysis of randomized trials.

Author

Biello, Federica, primary, Pinato, David James, additional, Borra, Gloria, additional, Genestroni, Silvia, additional, Siffredi, Guido, additional, Repetti, Ilaria, additional, Martini, Veronica, additional, Varughese, Feba mariam, additional, Vachanaram, Ajay Ram, additional, Mora, Edoardo, additional, Nardin, Simone, additional, Bruzzi, Paolo, additional, Sica, Antonio, additional, and Gennari, Alessandra, additional

Published
2020
Full Text
View/download PDF

55. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.

Author

Sharma, Rohini, primary, Hajiev, Saur, additional, Aval, Leila Motedayan, additional, Bettinger, Dominik, additional, Arizumi, Tadaaki, additional, Pirisi, Mario, additional, Rimassa, Lorenza, additional, Personeni, Nicola, additional, Pressiani, Tiziana, additional, Giordano, Laura, additional, Kudo, Masatoshi, additional, Thimme, Robert, additional, Park, Joong-Won, additional, Taddei, Tamar Hamosh, additional, Kaplan, David Edward, additional, Ramaswami, Ramya, additional, Pinato, David James, additional, and Allara, Elias, additional

Published
2020
Full Text
View/download PDF

56. Impact of baseline and concomitant corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy.

Author

Pinato, David James, primary, Kaseb, Ahmed Omar, additional, Wang, Yinghong, additional, Saeed, Anwaar, additional, Szafron, David, additional, Jun, Tomi, additional, Naqash, Abdul Rafeh, additional, Lee, ChiehJu, additional, Khan, Uqba, additional, Nimkar, Neil Satish, additional, Paul, Sonal, additional, Bettinger, Dominik, additional, Hildebrand, Hannah, additional, Pressiani, Tiziana, additional, Abugabal, Yehia I., additional, Personeni, Nicola, additional, Huang, Yi-Hsiang, additional, Rimassa, Lorenza, additional, Ang, Celina, additional, and Marron, Thomas Urban, additional

Published
2020
Full Text
View/download PDF

57. First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Author

Sarker, Debashis, primary, Sodergren, Mikael, additional, Plummer, Elizabeth Ruth, additional, Basu, Bristi, additional, Meyer, Tim, additional, Huang, Kai-Wen, additional, Evans, T.R. Jeffry, additional, Spalding, Duncan, additional, Ma, Yuk Ting, additional, Palmer, Daniel H., additional, Chee, Cheng Ean, additional, Pinato, David James, additional, Reebye, Vikash, additional, McVeigh, Daniel, additional, Raulf, Nina, additional, Vasara, Jenni, additional, Andrikakou, Pinelopi, additional, Habib, Robert, additional, Blakey, David, additional, and Habib, Nagy A., additional

Published
2020
Full Text
View/download PDF

60. Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice.

Author

Pinato, David James, primary, Howlett, Sarah, additional, Ottaviani, Diego, additional, Urus, Heather, additional, Patel, Aisha, additional, Mineo, Takashi, additional, Brock, Cathryn, additional, Power, Danielle, additional, Hatcher, Olivia, additional, Falconer, Alison, additional, Ingle, Manasi, additional, Brown, Anna, additional, Gujral, Dorothy M., additional, Partridge, Sarah, additional, Sarwar, Naveed, additional, Gonzalez, Michael, additional, Bendle, Maggie, additional, Lewanski, Conrad R., additional, Newsom-Davis, Thomas, additional, and Bower, Mark, additional

Published
2019
Full Text
View/download PDF

61. Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: The Blueprint-HCC study.

Author

Pinato, David James, primary, Mauri, Francesco A, additional, Spina, Paolo, additional, Cain, Owen, additional, Siddique, Abdul, additional, Goldin, Robert D, additional, Victor, Stephane, additional, Pizio, Corinna, additional, Akarca, Ayse, additional, Boldorini, Renzo, additional, Mazzucchelli, Luca, additional, Black, James M, additional, Shetty, Shishir, additional, Marafioti, Teresa, additional, and Sharma, Rohini, additional

Published
2018
Full Text
View/download PDF

63. Intra-tumour heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).

Author

Pinato, David James, primary, Victor, Stephane, additional, Spina, Paolo, additional, Trivedi, Pritesh, additional, Pirisi, Mario, additional, Burlone, Michela, additional, Black, James M, additional, Minisini, Rosalba, additional, Leutner, Monica, additional, Boldorini, Renzo, additional, Mauri, Francesco A, additional, and Sharma, Rohini, additional

Published
2017
Full Text
View/download PDF

64. Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study

Author

Yen, Clarence, primary, Sharma, Rohini, additional, Rimassa, Lorenza, additional, Arizumi, Tadaaki, additional, Bettinger, Dominik, additional, Choo, Huay Yee, additional, Pressiani, Tiziana, additional, Burlone, Michela E., additional, Pirisi, Mario, additional, Giordano, Laura, additional, Abdulrahman, Anisa, additional, Kudo, Masatoshi, additional, Thimme, Robert, additional, Park, Joong Won, additional, and Pinato, David James, additional

Published
2017
Full Text
View/download PDF

65. Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.

Author

Pinato, David James, primary, Brown, Matthew, additional, White, Solomon D T, additional, Zhang, Hua, additional, Toloue, Samin, additional, Dina, Roberto, additional, Trivedi, Pritesh, additional, Stebbing, Justin, additional, Mauri, Francesco A, additional, and Sharma, Rohini, additional

Published
2016
Full Text
View/download PDF

68. Prognostic subclassification of Intermediate Hepatocellular Carcinoma (I-HCC): a multicentre cohort study with propensity score analysis.

Author

Ramaswami, Ramya, primary, Pinato, David James, additional, Kubota, Keiichi, additional, Ishizuka, Mitsuru, additional, Arizumi, Tadaaki, additional, Kudo, Masatoshi, additional, Jang, Jeong Won, additional, Kim, Young Woon, additional, Pirisi, Mario, additional, Allara, Elias, additional, and Sharma, Rohini, additional

Published
2015
Full Text
View/download PDF

71. A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.

Author

Omlin, Aurelius Gabriel, primary, Spicer, James F., additional, Sarker, Debashis, additional, Pinato, David James, additional, Agarwal, Roshan, additional, Cassier, Philippe Alexandre, additional, Stavraka, Chara, additional, Blanco, Monsterrat, additional, Suder, Aneta, additional, Allan, Suzanne, additional, Heaton, Simon, additional, Decordova, Shaun, additional, Pope, Lorna, additional, Prince, Jenny, additional, Noguchi, Kohei, additional, Jones, Keith, additional, Inatani, Michiyasu, additional, Shiokawa, Rie, additional, Banerji, Udai, additional, and Blagden, Sarah Patricia, additional

Published
2012
Full Text
View/download PDF

74. New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.

Author

Mauro, Ezequiel, Rodríguez‐Perálvarez, Manuel, D'Alessio, Antonio, Crespo, Gonzalo, Piñero, Federico, De Martin, Eleonora, Colmenero, Jordi, Pinato, David James, and Forner, Alejandro

Subjects
*IMMUNE checkpoint inhibitors, *LIVER transplantation, *GRAFT rejection, *THERAPEUTICS, *HEPATOCELLULAR carcinoma
Abstract

ABSTRACT Background and Aims Methods and Results Despite liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC), particularly in patients with impaired liver function, the shortage of donors has forced the application of very restrictive criteria for selecting ideal candidates for whom LT can offer the best outcome. With the evolving LT landscape due to the advent of direct‐acting antivirals (DAAs) and the steady increase in donors, major efforts have been made to expand the transplant eligibility criteria for HCC. In addition, the emergence of immune checkpoint inhibitors (ICIs) for the treatment of HCC, with demonstrated efficacy in earlier stages, has revolutionized the therapeutic approach for these patients, and their integration in the setting of LT is challenging. Management of immunological compromise from ICIs, including the wash‐out period before LT and post‐LT immunosuppression adjustments, is crucial to balance the risk of graft rejection against HCC recurrence. Additionally, the effects of increased immunosuppression on non‐hepatic complications must be understood to prevent them from becoming obstacles to long‐term OS.In this review, we will evaluate the emerging evidence and its implications for the future of LT in HCC. Addressing these novel challenges and opportunities, while integrating the current clinical evidence with predictive algorithms, would ensure a fair balance between individual patient needs and the overall population benefit in the LT system. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

77. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Author

Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccia R, Hsu WF, Vivaldi C, Wietharn B, Lin RP, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon HJ, Cammà C, and Pinato DJ

Abstract

Background and Aims: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation over tumor progression in influencing overall survival (OS) has not been assessed in combination immunotherapy recipients., Approach and Results: From the AB-real observational study (n = 898), we accrued 571 patients with advanced/unresectable hepatocellular carcinoma, Child-Pugh A class treated with frontline atezolizumab + bevacizumab (AB). Hepatic decompensation and tumor progression during follow-up were studied in relationship to patients' OS using a time-dependent Cox model. Baseline characteristics were evaluated as predictors of decompensation in competing risks analysis. During a median follow-up of 11.0 months (95% CI: 5.1-19.7), 293 patients (51.3%) developed tumor progression without decompensation, and 94 (16.5%) developed decompensation. In multivariable time-dependent analysis, decompensation (HR: 19.04, 95% CI: 9.75-37.19), hepatocellular carcinoma progression (HR: 9.91, 95% CI: 5.85-16.78), albumin-bilirubin (ALBI) grade 2/3 (HR: 2.16, 95% CI: 1.69-2.77), and number of nodules >3(HR: 1.63, 95% CI: 1.28-2.08) were independently associated with OS. Pretreatment ALBI grade 2/3 (subdistribution hazard ratio [sHR]: 3.35, 95% CI: 1.98-5.67) was independently associated with decompensation, whereas viral etiology was protective (sHR: 0.55, 95% CI: 0.34-0.87). Among patients with viral etiology, effective antiviral treatment was significantly associated with a lower risk of decompensation (sHR: 0.48, 95% CI: 0.25-0.93)., Conclusions: Hepatic decompensation identifies patients with the worst prognosis following AB and is more common in patients with baseline ALBI >1 and nonviral etiology. Effective antiviral treatment may protect from decompensation, highlighting the prognostic disadvantage of patients with nonviral etiologies and the importance of multidisciplinary management to maximize OS., (Copyright © 2024 American Association for the Study of Liver Diseases.)

Published
2024
Full Text
View/download PDF

78. Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study.

Author

Bellan M, Apostolo D, Albè A, Crevola M, Errica N, Ratano G, Tonello S, Minisini R, D'Onghia D, Baricich A, Patrucco F, Zeppegno P, Gramaglia C, Balbo PE, Cappellano G, Casella S, Chiocchetti A, Clivati E, Giordano M, Manfredi M, Patti G, Pinato DJ, Puricelli C, Raineri D, Rolla R, Sainaghi PP, and Pirisi M

Subjects
Humans, Adult, Female, Prospective Studies, SARS-CoV-2, Post-Acute COVID-19 Syndrome, Interleukin-12, Cytokines, Disease Progression, COVID-19
Abstract

Rationale: Factors associated with long-term sequelae emerging after the acute phase of COVID-19 (so called "long COVID") are unclear. Here, we aimed to identify risk factors for the development of COVID-19 sequelae in a prospective cohort of subjects hospitalized for SARS-CoV-2 infection and followed up one year after discharge., Methods: A total of 324 subjects underwent a comprehensive and multidisciplinary evaluation one year after hospital discharge for COVID-19. A subgroup of 247/324 who consented to donate a blood sample were tested for a panel of circulating cytokines., Results: In 122 patients (37.8%) there was evidence of at least one persisting physical symptom. After correcting for comorbidities and COVID-19 severity, the risk of developing long COVID was lower in the 109 subjects admitted to the hospital in the third wave of the pandemic than in the 215 admitted during the first wave, (OR 0.69, 95%CI 0.51-0.93, p=0.01). Univariable analysis revealed female sex, diffusing capacity of the lungs for carbon monoxide (DLCO) value, body mass index, anxiety and depressive symptoms to be positively associated with COVID-19 sequelae at 1 year. Following logistic regression analysis, DLCO was the only independent predictor of residual symptoms (OR 0.98 CI 95% (0.96-0.99), p=0.01). In the subgroup of subjects with normal DLCO (> 80%), for whom residual lung damage was an unlikely explanation for long COVID, the presence of anxiety and depressive symptoms was significantly associated to persistent symptoms, together with increased levels of a set of pro-inflammatory cytokines: interferon-gamma, tumor necrosis factor-alpha, interleukin (IL)-2, IL-12, IL-1β, IL-17. In logistic regression analysis, depressive symptoms (p=0.02, OR 4.57 [1.21-17.21]) and IL-12 levels (p=0.03, OR 1.06 [1.00-1.11]) 1-year after hospital discharge were independently associated with persistence of symptoms., Conclusions: Long COVID appears mainly related to respiratory sequelae, prevalently observed during the first pandemic wave. Among patients with little or no residual lung damage, a cytokine pattern consistent with systemic inflammation is in place., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Bellan, Apostolo, Albè, Crevola, Errica, Ratano, Tonello, Minisini, D’Onghia, Baricich, Patrucco, Zeppegno, Gramaglia, Balbo, Cappellano, Casella, Chiocchetti, Clivati, Giordano, Manfredi, Patti, Pinato, Puricelli, Raineri, Rolla, Sainaghi, Pirisi and the No-More COVID study group.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results